down arrow

Shenzhen Salubris Pharmaceuticals Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000FW8
CNY
60.50
0.72 (1.2%)

Dec 05

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Why is Shenzhen Salubris Pharmaceuticals Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 2.35% and Operating profit at 10.53% over the last 5 years
2
Flat results in Jun 25
  • DEBT-EQUITY RATIO (HY) Highest at -25.13 %
  • DEBTORS TURNOVER RATIO(HY) Lowest at 4.01%
  • INTEREST(Q) Highest at CNY 4.97 MM
3
With ROE of 7.28%, it has a fair valuation with a 7.15 Price to Book Value
  • Over the past year, while the stock has generated a return of 82.90%, its profits have fallen by -1.5%
  • At the current price, the company has a high dividend yield of 0.9
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shenzhen Salubris Pharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Shenzhen Salubris Pharmaceuticals Co., Ltd.
79.42%
2.63
45.31%
China Shanghai Composite
15.19%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
2.35%
EBIT Growth (5y)
10.53%
EBIT to Interest (avg)
32.71
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.44
Tax Ratio
3.14%
Dividend Payout Ratio
92.59%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.91%
ROE (avg)
7.07%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
98
Industry P/E
Price to Book Value
7.15
EV to EBIT
114.91
EV to EBITDA
62.65
EV to Capital Employed
9.21
EV to Sales
14.55
PEG Ratio
NA
Dividend Yield
0.91%
ROCE (Latest)
8.02%
ROE (Latest)
7.28%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 1,122.2 MM

NET SALES(Q)

Highest at CNY 1,054.28 MM

RAW MATERIAL COST(Y)

Fallen by -6.69% (YoY

-13What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at -25.13 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.01%

INTEREST(Q)

Highest at CNY 4.97 MM

Here's what is working for Shenzhen Salubris Pharmaceuticals Co., Ltd.
Operating Cash Flow
Highest at CNY 1,122.2 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales
Highest at CNY 1,054.28 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (CNY MM)

Raw Material Cost
Fallen by -6.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shenzhen Salubris Pharmaceuticals Co., Ltd.
Interest
At CNY 4.97 MM has Grown at 14.29%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest
Highest at CNY 4.97 MM
in the last five periods and Increased by 14.29% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio
Highest at -25.13 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 4.01%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."